Stop Leaving Diagnostic Revenue on the Table—Here's Why Your Billing Is Broken

Cardiovascular disease costs the U.S. healthcare system more than $500 billion annually — and according to the American Heart Association, that figure is projected to triple to $1.8 trillion by 2050. Internal medicine practices sit at the front line of that crisis, yet most have had no viable point-of-care tool to act on it — until now.

The CorVista System is an FDA-cleared, AI-powered cardiovascular diagnostic platform that detects coronary artery disease and pulmonary hypertension directly in the internist's office — no radiation, no fasting, no hospital referral required. In September 2023, CorVista Health received FDA 510(k) clearance for its CAD Add-On, validated across 1,816 patients with 88% sensitivity and a 99% negative predictive value.

What makes this relevant to practice administrators right now: as of July 1, 2026, the AMA assigned CPT code 1104T to CorVista's AI analysis, effective January 1, 2027 — giving practices a concrete billing code to build into their 2027 revenue cycle today.

What You Need to Know About CorVista Diagnostic Billing Revenue for Practice Administrators

Three things happened in quick succession that every internal medicine practice administrator needs to understand: CorVista received FDA clearance, then a Mayo Clinic collaboration, then — as of July 1, 2026 — a dedicated AMA Category III CPT code. That sequence is not coincidence. It is a reimbursement pathway being built in real time.

CPT code 1104T, effective January 1, 2027, covers augmentative AI algorithmic analysis of potential CAD, pulmonary hypertension, and elevated pulmonary capillary wedge pressure. According to CorVista Health (BusinessWire, July 2026), Category III codes are used by physicians, hospitals, and public and private health insurance programs to track utilization and build the data foundation for Category I reimbursement.

That last point matters. This is not a dead end — it is the standard regulatory on-ramp. HeartFlow followed this exact path: Category III in 2021, Category I with full Medicare RVUs established for 2026.

The billing structure is equally worth noting:

• Administering physician bills insurance for performing the test
• CorVista collects the reading/interpretation fee separately
• No capital purchase required — practices generate diagnostic revenue without device ownership costs

At ACC.26 in March 2026, CorVista's machine-learning model demonstrated 90% sensitivity and 99% negative predictive value for ischemia detection in symptomatic patients — clinical performance that supports the billing case to payers.

As Nikki Troiano Gainey, Chief Customer Officer at CorVista Health, put it: "Cardiovascular disease diagnosis remains too slow and too fragmented. CorVista has the potential to bring advanced cardiopulmonary insight to the initial point of care."

Key Strategies and Best Practices

The billing model is the strategy. Under CorVista's current arrangement, the administering physician bills insurance for the test while CorVista collects the reading fee — zero capital outlay, zero device purchase, no leased equipment sitting idle between uses. According to Birmingham Medical News, that is exactly how Cullman Internal Medicine structured it — and Dr. Tracy Neal, cardiologist at the affiliated clinic, put it plainly: "We don't pay anything at all, so it was a no-brainer for us to incorporate it."

Three priorities determine whether a practice captures maximum value from this model:

• Identify your existing cardiac-risk patient population now. Patients with hypertension, dyslipidemia, diabetes, or unexplained dyspnea are already in your schedule. They are the immediate billing pool — no new patient acquisition required.
• Document CPT 1104T into your 2027 revenue cycle plan today. The AMA code is issued. The billing infrastructure exists. Practices that wait until January 2027 to start planning will lose a full year of utilization data — data that matters when Category I conversion comes.
• Use the misdiagnosis data to justify internal protocol changes. The Journal of Cardiac Failure found heart failure misdiagnosis rates reach 68.5% when general practitioners refer to specialists — meaning the diagnostic gap is happening in your office, not the cardiologist's.

The HeartFlow precedent is your roadmap. HeartFlow's AI cardiac diagnostic went from Category III CPT in 2021 to full Category I Medicare reimbursement in 2024. CorVista is on the same path. Practices building utilization volume under 1104T now are positioning for full RVU-based reimbursement when that conversion happens.

Common Mistakes to Avoid

Dismissing cardiovascular symptoms as anxiety or deconditioning is the most expensive diagnostic error an internal medicine practice can make — clinically and legally. According to a peer-reviewed multinational survey published in Therapeutic Advances in Respiratory Disease (2024), 51.3% of U.S. PAH patients were misdiagnosed, and the average patient saw 2.9 physicians before receiving a correct diagnosis. Those 2.9 physicians each absorbed liability exposure that a single point-of-care screening could have collapsed into one visit.

Three operational mistakes consistently undermine practices that could be capturing this revenue:

• Waiting for cardiology to lead. PAH diagnosis delay averages 2.5 to 3.9 years from symptom onset, according to a retrospective analysis of U.S. healthcare claims data published in PMC/NIH — and that delay starts in your waiting room, not a cardiologist's office.
• Treating Category III CPT codes as unserious. HeartFlow followed the identical Category III pathway starting in 2021 and converted to a full Category I CPT code with established CMS RVUs by 2024. The code is a milestone, not a dead end.
• Assuming ancillary revenue requires capital risk. Reports from Cullman Internal Medicine's deployment suggest the practice incurred no upfront device cost — CorVista collects the reading fee while the administering physician bills separately for the test.

The patients generating these missed diagnoses are already scheduled. The mistake is letting them leave without a screening that could have billed, detected, and protected — in the same visit.

Practical Next Steps

Missed cardiac diagnoses are not just clinical failures — they are financial and legal liabilities. According to the American College of Cardiology, diagnosis-related allegations were the most common complaint in 1,180 malpractice claims against internal medicine physicians — with myocardial infarction among the top missed diagnoses. Acting now is not optional.

Here is where to focus your next 90 days:

1. Request a CorVista workflow assessment. Understand how the system integrates into your current patient flow — no capital outlay required. The billing model means your practice bills for administration while CorVista handles interpretation.
2. Lock in your 2027 revenue cycle plan around CPT code 1104T. The AMA code is effective January 1, 2027. Your billing team needs to be ready before it goes live.
3. Audit your PAH screening gaps now. According to Therapeutic Advances in Respiratory Disease (2024), 71.6% of PAH patients first presented to a primary care physician — and 51.3% in the U.S. were misdiagnosed. Those patients are already in your chairs.
4. Review the HeartFlow precedent. HeartFlow converted a Category III CPT code to Category I in three years with full CMS reimbursement. That is the established roadmap CorVista is now on.

According to PharmacoEconomics – Open (2024), PAH diagnosis delays beyond 24 months generate $5,366 in excess costs per patient per month — driven by hospitalizations your practice could have prevented with an earlier flag.

The infrastructure is in place. The billing code exists. The clinical evidence is peer-reviewed. The only remaining variable is your timeline.

Three things converged in 2026 that internal medicine practices cannot afford to ignore: a dedicated AMA CPT code (1104T, effective January 1, 2027), a formal Mayo Clinic research collaboration, and a cardiovascular underdiagnosis crisis that is only getting worse. Coronary artery disease alone affects more than 20 million U.S. adults, according to the Methodist DeBakey Cardiovascular Journal — and the patients carrying that burden are already sitting in your waiting room.

According to HealthWright Technologies, ancillary diagnostic services remain one of the last viable revenue growth levers for independent primary care practices operating in a flat-reimbursement environment. CorVista turns that lever into a structured billing opportunity — no capital outlay, no added staff, no new patient acquisition required.

The regulatory trajectory matters too. Unislink RCM's analysis of the AMA's 2026 CPT updates confirmed that AI-augmented billing codes entered the AMA code set for the first time in history this cycle — with physicians retaining final interpretive responsibility. That is the exact framework CorVista operates within. This is not an experiment. It is a reimbursement structure the AMA just formally validated.

Practices that act in 2026 build the operational experience before CPT 1104T goes live in January 2027. That is a measurable first-mover advantage in your revenue cycle.

Want to see what CorVista diagnostic billing looks like inside an internal medicine practice? Connect with the Perfect Rhythm team to review the billing model, CPT 1104T implementation timeline, and what your patient panel could realistically generate.

Frequently Asked Questions

What is CPT code 1104T and how does it apply to CorVista?

CPT code 1104T is a new AMA Category III code granted to CorVista Health as of July 1, 2026, effective January 1, 2027. It covers augmentative AI algorithmic analysis of potential coronary artery disease, pulmonary hypertension, and elevated pulmonary capillary wedge pressure — the exact conditions the CorVista System is FDA-cleared to screen for at the point of care.

Does an internal medicine practice need to purchase the CorVista device?

No upfront capital purchase is required under CorVista's current billing model. The administering physician bills insurance for performing the test, while CorVista collects the reading and interpretation fee — making it a zero-capital ancillary revenue stream for the practice.

How accurate is the CorVista System for detecting coronary artery disease?

The CorVista System's CAD Add-On demonstrated 88% sensitivity and a 99% negative predictive value in the IDENTIFY study across 1,816 patients — performance comparable to coronary CT angiography for rule-out purposes, according to CorVista Health's FDA clearance announcement.

Can internal medicine physicians use CorVista to screen for pulmonary hypertension?

Yes. The CorVista PH Add-On received FDA clearance in April 2024 after receiving FDA Breakthrough Device Designation, making it the only point-of-care AI system cleared for both CAD and pulmonary hypertension detection. It requires no fasting, no radiation, and no injections.

Is a Category III CPT code the same as full Medicare reimbursement?

Not yet — Category III codes are temporary tracking codes used while utilization data and clinical evidence accumulate toward a Category I designation with established RVUs. HeartFlow followed this exact pathway, converting its AI cardiac diagnostic Category III code to a fully reimbursed Category I code in 2024, which serves as the established precedent for CorVista's trajectory.